Icomix

Helium, Carbon Monoxide, the active ingredient in Icomix, is a medical gas presented as an inhalation gas for inhalation use. It is employed in respiratory therapy for diagnostic and therapeutic applications in hospital settings.

GNH USA supplies Icomix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Icomix is used in respiratory therapy and diagnostic procedures involving the pulmonary system. - Pulmonary function testing: Helium‑oxygen mixture improves measurement accuracy by reducing airway turbulence. - Ventilation‑perfusion scanning: Carbon monoxide component serves as a radiotracer to assess regional lung perfusion. - Airway obstruction management: Heliox can decrease airway resistance and improve ventilation in patients with obstructive airway disease.

Adverse reactions may occur with inhalation of medical gases and should be monitored.

Common Side Effects: - Cough or throat irritation - Dizziness or light‑headedness - Headache - Nausea - Mild hypoxia - Transient increase in heart rate

Serious or Rare Side Effects: - Carbon monoxide poisoning leading to severe hypoxemia - Loss of consciousness - Arrhythmias - Pulmonary edema - Methemoglobinemia - Severe respiratory depression

Careful assessment and monitoring are required when using Icomix. - Assess respiratory status: evaluate baseline lung function before administration. - Monitor oxygen saturation: continuous pulse‑oximetry during inhalation. - Avoid use in severe anemia: reduced hemoglobin limits oxygen transport. - Limit exposure duration: follow institutional protocols for gas delivery time. - Use only under qualified supervision: trained personnel must administer and supervise. - Store at ambient temperature: keep cylinders upright, protect from heat and direct sunlight.

Icomix may interact with other agents affecting gas exchange or hemoglobin binding.

Major Interactions (Avoid): - Concurrent high‑concentration oxygen therapy: may alter gas mixture efficacy. - Use with nitrous oxide anesthesia: increased risk of hypoxia. - Co‑administration with agents that raise carboxyhemoglobin (e.g., sodium nitrite).

Moderate Interactions (Monitor Closely): - Anticoagulants: potential additive bleeding risk with carbon monoxide exposure. - Bronchodilators: possible additive airway effects. - Sedatives or opioids: enhanced respiratory depression may occur.